Cargando…
Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification
PURPOSE: Lung cancer (LC) is the most commonly diagnosed cancer and the leading cause of cancer-related deaths. More and more long noncoding RNA (lncRNA) are associated with cancer. This study aimed to assess whether plasma lncRNA could be used to diagnose early-stage LC and identify subtypes of LC....
Autores principales: | Liu, Xiaofeng, Chen, Wenyan, Qi, Yu, Zhu, Yongqian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492367/ https://www.ncbi.nlm.nih.gov/pubmed/36159563 http://dx.doi.org/10.1155/2022/5702014 |
Ejemplares similares
-
Retracted: Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
LncRNA FOXD1‐AS1 acts as a potential oncogenic biomarker in glioma
por: Gao, Yuan‐Feng, et al.
Publicado: (2019) -
Emerging Roles and Mechanisms of lncRNA FOXD3-AS1 in Human Diseases
por: Yao, Qinfan, et al.
Publicado: (2022) -
LncRNA FOXD2-AS1 Increased Proliferation and Invasion of Lung Adenocarcinoma via Cell-Cycle Regulation
por: Yuan, Yuan, et al.
Publicado: (2023) -
Knockdown of lncRNA FOXD2-AS1 Inhibits Proliferation, Migration, and Drug Resistance of Breast Cancer Cells
por: Nong, Qiaohong, et al.
Publicado: (2021)